Galapagos NV

Amsterdam Stock Exchange GLPG.AS

Galapagos NV Return on Assets (ROA) for the year ending December 31, 2023: 4.86%

Galapagos NV Return on Assets (ROA) is 4.86% for the year ending December 31, 2023, a 205.51% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Galapagos NV Return on Assets (ROA) for the year ending December 31, 2022 was -4.60%, a -90.65% change year over year.
Galapagos NV Return on Assets (ROA) for the year ending December 31, 2021 was -2.42%, a 55.60% change year over year.
Galapagos NV Return on Assets (ROA) for the year ending December 31, 2020 was -5.44%, a -320.29% change year over year.
Galapagos NV Return on Assets (ROA) for the year ending December 31, 2019 was 2.47%, a 221.48% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Amsterdam Stock Exchange: GLPG.AS

Galapagos NV

CEO	Dr. Paulus A. Stoffels M.D., Ph.D.
IPO Date	May 6, 2005
Location	Belgium
Headquarters	Generaal De Wittelaan L11 A3
Employees	1,123
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Clinical Trials Composite Materials Drugstores & Retail Pharmacies Vaccines

Description

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Key trends

Past 5 years